Pharma could have ‘immense influence’ in combatting the opioid crisis, says expert

By Flora Southey contact

- Last updated on GMT

(Image: Getty/ah_designs)
(Image: Getty/ah_designs)

Related tags: Opioid epidemic

The US opioid crisis has been driven by early use in standard care, says Opiant director Gabrielle Silver, who urges pharma to ‘think differently’ to enable change.

Prescription opioid addiction and abuse is a public health emergency​ in the US, with approximately 130 deaths recorded daily between 2016 and 2017 from opioid-related drug overdoses.

This North American-based issue is now “heading over here” ​to Europe, according to Gabrielle Silver, general manager of LloydsPharmacy Clinical Homecare in the UK, and lead independent director of Opiant Pharmaceuticals in California.

“One of the reasons why there is such a high level of opioid addiction [in the US] is because physicians in their training are not taught in the same way [as in the UK],” ​said Silver at Pharma Integrates, in London, yesterday.

In the US, “very different sorts of levels of motivations” ​influence physicians, driven by the consumer push, a need to differentiate between brands, and a pressure to retain patient populations, explained Silver.

These factors can lead to the early prescription of opioid-based painkillers, she added: “The early use of opioid drugs in standard care is the reason why there is a huge opioid crisis.”

‘Pharma can do more’

According to Silver, both industry and academia can work to promote change, by asking the question: “How can we instil again, with absolute focus and clarity, the teaching that says ‘This is not the way to manage pain, there are multiple ways to manage pain’?”

Could investing in specific pain physicians be a solution?, she asked delegates.

“Pharma can think differently…We have to understand that unless we invest now, we are going to go in that [North American] direction,” ​she added.  “Pharma has immense influence and I know that they can do so much to try and push things forward.”

“I’ve got nothing but respect for what pharma can achieve and have achieved, but they can do more. It’s up to them to move beyond this [traditional] transactional relationship.”

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more